NAFLD is now the most common cause of liver disease in Western countries. This Review
explores the links between NAFLD, the metabolic syndrome, dysbiosis, poor diet and gut …

Background Sarcopenia (loss of muscle mass) is common in cirrhosis and is associated with
poor outcomes. Current teaching recommends the use of protein supplementation and …

The renin–angiotensin system (RAS) is a key regulator of vascular resistance, sodium and
water homeostasis and the response to tissue injury. Historically, angiotensin II (Ang II) was …

BACKGROUND & AIMS:: Adefovir dipivoxil effectively inhibits both hepatitis B virus (HBV)
replication and disease activity in patients with chronic hepatitis B. Resistance to treatment …

Background Treatment options are limited for patients infected by hepatitis C virus (HCV)
with advanced liver disease. We assessed the safety and efficacy of ledipasvir, sofosbuvir …

Background Present interferon-based standard of care treatment for chronic hepatitis C virus
(HCV) infection is limited by both efficacy and tolerability. We assessed the safety …

Background: Angiotensin converting enzyme (ACE) 2 is a recently identified homologue of
ACE that may counterregulate the actions of angiotensin (Ang) II by facilitating its breakdown …

BACKGROUND Wilson's disease is a rare but treatable condition that often presents
diagnostic dilemmas. These dilemmas have for the most part not been resolved by the …

Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced
liver disease, are a challenging population in urgent need of optimally effective therapies …

Background & Aims: High-dose intravenous hepatitis B immunoglobulin (HBIG) may prevent
recurrent hepatitis B virus (HBV) infection, but the cost has limited its widespread use in …